The glucagon component increases energy expenditure and helps your body burn fat more efficiently
Vendors with more extensive third-party testing databases and higher independent ratings may be more appropriate for studies where absolute purity is critical
People report that hunger does not spike dramatically in the days before their next injection, which is a common complaint with some shorter-acting compounds
Should my dose schedule, titration speed, or meal plan be adjusted
Other Key Findings Metabolic improvements: Participants saw reductions in A1C (for those with prediabetes or diabetes), fasting glucose, and triglycerides Liver fat reduction: Retatrutide reduced liver fat by up to 50%, which is why Eli Lilly added a NASH-specific trial to the Phase 3 program Side effects: Mostly gastrointestinal (nausea, diarrhea, constipation), similar to other GLP-1 drugs but manageable with slow titration Discontinuation rate: About 10% of participants stopped due to side effects, comparable to tirzepatide and semaglutide Study limitation: The Phase 2 trial was only 48 weeks long
01053-X/asset/68ad1d8b-bb7e-4ca0-8f89-99384d885ca3/main.assets/gr2.jpg)
